The effects of
HSR-902, an
antimuscarinic agent, on development of various gastric and duodenal lesions, gastric secretion, pupil size and salivation in rats were compared with those of
pirenzepine.2HC1 (
pirenzepine, antiulcer agent) and
timepidium bromide (timepidium,
antispasmodic). 1) HSR-902 (10-100 mg/kg), given orally, dose-dependently inhibited the developments of gastric lesions induced by water-immersion stress,
aspirin,
indomethacin,
serotonin and
reserpine and duodenal lesions induced by
cysteamine and
mepirizole. The activities of
HSR-902 were almost equal or somewhat more potent than those of
pirenzepine, and they were more potent than those of timepidium. 2)
HSR-902 (30 and 100 mg/kg, p.o.), when examined using pylorus-ligated preparations, dose-dependently inhibited the gastric acid output,
pepsin output, and gastric acid and
pepsin concentrations, but did not inhibit the gastric volume (
HSR-902, in a higher dose, slightly increased the gastric volume.).
Pirenzepine (100 mg/kg, p.o.), like
atropine sulfate, inhibited the gastric volume,
acid output and
pepsin output, but did not inhibit the gastric acid and
pepsin concentrations. Timepidium (100 mg/kg, p.o.), however, hardly influenced these parameters except for increasing the gastric volume. 3)
HSR-902 (100 mg/kg, p.o.) induced the mydoriasis and inhibited the
pilocarpine-induced salivation, and its activities were less potent than those of
pirenzepine. These results suggest that
HSR-902 is a promising agent for the treatment of
peptic ulcer.